117 related articles for article (PubMed ID: 9893657)
1. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia.
Frasci G; Comella P; Panza N; De Cataldis G; Del Gaizo F; Pozzo C; Gravina A; Ruffolo P; Cioffi R; Marcatili P; Della Vittoria M; Monfardini S; Comella G
Eur J Cancer; 1998 Oct; 34(11):1710-4. PubMed ID: 9893657
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin.
Yilmaz U; Polat G; Anar C; Halilcolar H
Indian J Cancer; 2011; 48(4):454-9. PubMed ID: 22293260
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study.
Gridelli C; Rossi A; Scognamiglio F; Guida C; Fiore F; Gatani T; Scoppa G; Pergola M
Anticancer Res; 1997; 17(6D):4755-8. PubMed ID: 9494602
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.
Frasci G; Perillo G; Comella G; Comella P; Polverino M; Menzella G; Persico G
Cancer; 1995 Apr; 75(7):1578-85. PubMed ID: 8826913
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.
Johnson DH; DeVore R; Greco FA; Walls J; Thomas M; Hande KR; Hainsworth JD
Semin Oncol; 1992 Feb; 19(1 Suppl 2):50-6. PubMed ID: 1329223
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
11. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis.
Bardet E; Rivière A; Charloux A; Spaeth D; Ducoloné A; Le Groumellec A; Pellae-Cosset B; Henry-Amar M; Douillard JY
Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):163-8. PubMed ID: 9212019
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.
Miller AA; Niell HB
Lung Cancer; 2001; 33(2-3):241-8. PubMed ID: 11551419
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).
Langer CJ; McAleer CA; Bonjo CA; Litwin S; Millenson M; Kosierowski R; Blankstein K; Alexander R; Ozols RF
Eur J Cancer; 2000 Jan; 36(2):183-93. PubMed ID: 10741276
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer.
Jeremic B; Shibamoto Y; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):343-8. PubMed ID: 10760429
[TBL] [Abstract][Full Text] [Related]
17. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Charpidou A; Tsagouli S; Tsimpoukis S; Vassias A; Makrilia N; Stratakos G; Gkiozos I; Syrigos K
Anticancer Drugs; 2010 Jul; 21(6):651-5. PubMed ID: 20386306
[TBL] [Abstract][Full Text] [Related]
18. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):19-25. PubMed ID: 11316542
[TBL] [Abstract][Full Text] [Related]
19. Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?
Pfeiffer P; Sørensen P; Rose C
Eur J Cancer; 1995; 31A(1):64-9. PubMed ID: 7695981
[TBL] [Abstract][Full Text] [Related]
20. Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in Non-Small Cell Lung Cancer Stage IIIB/IV.
Maneechawakajorn J; Hathaisanguan S
J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S175-81. PubMed ID: 27266233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
